Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...

FRANKFURT: European shares closed slightly lower on Thursday after US President Donald Trump threatened to impose tariffs on ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

EUROPEAN shares closed slightly lower on Thursday after US President Donald Trump threatened to impose tariffs on alcoholic ...

European shares dipped amid escalating trade tensions as Trump threatens new tariffs on EU alcoholic products. Market ...

European stocks dipped in volatile trading, with beverage makers sliding after US President Donald Trump threatened to put a ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...